Syros Pharmaceuticals Down 70% After Hours Following Clinical Trial Update

Dow Jones08-13

By Josh Beckerman

Syros Pharmaceuticals shares fell 70% to $1.54 after hours as the company said it will discontinue enrollment in a clinical trial evaluating its tamibarotene in combination with two other drugs in certain patients with acute myeloid leukemia.

The SELECT-AML-1 Phase 2 trial is evaluating tamibarotene in combination with venetoclax and azacitidine, compared to the regimen of venetoclax and azacitidine.

Syros said that after an interim analysis, the probability for success of the SELECT-AML-1 study to demonstrate superiority at the final analysis was considered low.

There were no new safety signals associated with the combination. Patients currently enrolled in SELECT-AML-1 will have the opportunity to remain on study at the discretion of study investigators.

Syros continues to evaluate tamibarotene in combination with azacitidine in the SELECT-MDS-1 Phase 3 clinical with certain myelodysplastic syndrome patients.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

August 12, 2024 18:24 ET (22:24 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2459965103?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-13 06:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2459965103","market":"fut","top_or_hot":-1,"title":"Syros Pharmaceuticals Down 70% After Hours Following Clinical Trial Update","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     By Josh Beckerman \n</p>\n<p>\n  Syros Pharmaceuticals shares fell 70% to $1.54 after hours as the company said it will discontinue enrollment in a clinical trial evaluating its tamibarotene in combination with two other drugs in certain patients with acute myeloid leukemia. \n</p>\n<p>\n  The SELECT-AML-1 Phase 2 trial is evaluating tamibarotene in combination with venetoclax and azacitidine, compared to the regimen of venetoclax and azacitidine. \n</p>\n<p>\n  Syros said that after an interim analysis, the probability for success of the SELECT-AML-1 study to demonstrate superiority at the final analysis was considered low. \n</p>\n<p>\n  There were no new safety signals associated with the combination. Patients currently enrolled in SELECT-AML-1 will have the opportunity to remain on study at the discretion of study investigators. \n</p>\n<p>\n   Syros continues to evaluate tamibarotene in combination with azacitidine in the SELECT-MDS-1 Phase 3 clinical with certain myelodysplastic syndrome patients. \n</p>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 12, 2024 18:24 ET (22:24 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Syros Pharmaceuticals Down 70% After Hours Following Clinical Trial Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSyros Pharmaceuticals Down 70% After Hours Following Clinical Trial Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-13 06:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Josh Beckerman \n\n\n  Syros Pharmaceuticals shares fell 70% to $1.54 after hours as the company said it will discontinue enrollment in a clinical trial evaluating its tamibarotene in combination with...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2459965103","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2459965103","pubTimestamp":1723501440,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Syros Pharmaceuticals shares fell 70% to $1.54 after hours as the company said it will discontinue enrollment in a clinical trial evaluating its tamibarotene in combination with two other drugs in certain patients with acute myeloid leukemia.The SELECT-AML-1 Phase 2 trial is evaluating tamibarotene in combination with venetoclax and azacitidine, compared to the regimen of venetoclax and azacitidine.Syros said that after an interim analysis, the probability for success of the SELECT-AML-1 study to demonstrate superiority at the final analysis was considered low.There were no new safety signals associated with the combination. Patients currently enrolled in SELECT-AML-1 will have the opportunity to remain on study at the discretion of study investigators.Syros continues to evaluate tamibarotene in combination with azacitidine in the SELECT-MDS-1 Phase 3 clinical with certain myelodysplastic syndrome patients.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SYRS":"Syros Pharmaceuticals Inc."},"translate_title":"临床试验更新后，Syros Pharmaceuticals盘后股价下跌70%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYRS":1},"content_text":"By Josh Beckerman \n\n\n  Syros Pharmaceuticals shares fell 70% to $1.54 after hours as the company said it will discontinue enrollment in a clinical trial evaluating its tamibarotene in combination with two other drugs in certain patients with acute myeloid leukemia. \n\n\n  The SELECT-AML-1 Phase 2 trial is evaluating tamibarotene in combination with venetoclax and azacitidine, compared to the regimen of venetoclax and azacitidine. \n\n\n  Syros said that after an interim analysis, the probability for success of the SELECT-AML-1 study to demonstrate superiority at the final analysis was considered low. \n\n\n  There were no new safety signals associated with the combination. Patients currently enrolled in SELECT-AML-1 will have the opportunity to remain on study at the discretion of study investigators. \n\n\n   Syros continues to evaluate tamibarotene in combination with azacitidine in the SELECT-MDS-1 Phase 3 clinical with certain myelodysplastic syndrome patients. \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 12, 2024 18:24 ET (22:24 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459965103"}